Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma

Journal of Veterinary Internal Medicine

Volumn 25, Issue 4, 2011, Pages 920-926

  Burton, J H ^a   Mitchell, L ^a   Thamm, D H ^a   Dow, S W ^a   Biller, B J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Cancer; Canine; Chemotherapy; Metronomic

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOPSY; CLINICAL TRIAL; COHORT ANALYSIS; DOG; DOG DISEASE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; SARCOMA; SOFT TISSUE TUMOR; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPSY; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; IMMUNOPHENOTYPING; NEOVASCULARIZATION, PATHOLOGIC; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SARCOMA; SOFT TISSUE NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

ANIMALIA; CANIS FAMILIARIS; MUS;

EID: 79960561470     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0753.x     Document Type: Article

References (42)

1. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-1047.
2. Kerbel RS. The anti-angiogenic basis of metronomic chemotherapy. Nature reviews. Cancer 2004;4:423-436.
3. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-4346.
4. Hamano Y, Sugimoto H, Soubasakos MA, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64:1570-1574.
5. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
6. Baecher-Allan C, Anderson DE. Regulatory cells and human cancer. Semin Cancer Biol 2006;16:98-105.
7. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-811.
8. Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 2008;27:5886-5893.
9. Wilke CM, Wu K, Zhao E, et al. Prognostic significance of regulatory T cells in tumor. Int J Cancer 2010;127:748-758.
10. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
11. Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
12. Leong PP, Mohammad R, Ibrahim N, et al. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett 2006;102:229-236.
13. Biller BJ, Elmslie RE, Burnett RC, et al. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 2007;116:69-78.
14. O'Neill K, Guth A, Biller B, et al. Changes in regulatory T cells in dogs with cancer and associations with tumor type. J Vet Inter Med 2009;23:875-881.
15. Biller B, Guth A, Burton J, et al. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Inter Med 2010;24:1118-1123.
16. Tominaga M, Horiuchi Y, Ichikawa M, et al. Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma. J Vet Diagn Invest 2010;22:438-441.
17. Horiuchi Y, Tominaga M, Ichikawa M, et al. Increase of regulatory T cells in the peripheral blood of dogs with metastatic tumors. Microbiol Immunol 2009;53:468-474.
18. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+) 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-2868.
19. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-648.
20. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-344.
21. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008;22:1373-1379.
22. Lana S, U'Ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007;21:764-769.
23. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-1397.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
25. Walter CU, Biller BJ, Lana SE, et al. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 2006;20:342-347.
26. Faldyna M, Leva L, Knotigova P, et al. Lymphocyte subsets in peripheral blood of dogs-a flow cytometric study. Vet Immunol Immunopathol 2001;82:23-37.
27. Kamstock D, Elmslie R, Thamm D, et al. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007;56:1299-1309.
28. Kamstock D, Guth A, Elmslie R, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2006;13:306-317.
29. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19.
30. Luong RH, Baer KE, Craft DM, et al. Prognostic significance of intratumoral microvessel density in canine soft-tissue sarcomas. Vet Pathol Online 2006;43:622-631.
31. Betts GJ, Clarke SL, Richards HE, et al. Regulating the immune response to tumours. Adv Drug Delivery Rev 2006;58:948-961.
32. Horiuchi Y, Tominaga M, Ichikawa M, et al. Relationship between regulatory and type 1T cells in dogs with oral malignant melanoma. Microbiol Immunol 2010;54:152-159.
33. Rissetto KC, Rindt H, Selting KA, et al. Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma. Vet Immunol Immunopathol 2010;135:137-145.
34. Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010;70:4850-4858.
35. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-7051.
36. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-952.
37. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-893.
38. Chen CA, Ho CM, Chang MC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010;18:1233-1243.
39. Zhang B, Jia H, Liu J, et al. Depletion of regulatory T cells facilitates growth of established tumors: A mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. J Immunol 2010;185:7199-7206.
40. Liu P, Jaffar J, Hellstrom I, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother 2010;33:53-59.
41. Abrams VK, Hwang B, Lesnikova M, et al. A novel monoclonal antibody specific for canine CD25 (P4A10): Selection and evaluation of canine Tregs. Vet Immunol Immunopathol 2010;135:257-265.
42. Charney SC, Bergman PJ, Hohenhaus AE, et al. Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). J Am Vet Med Assoc 2003;222:1388-1393.